Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis many of them are already advanced and difficult to treat. We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. This resulted in a significant downstaging of the tumor and allowed its subsequent complete surgical removal. Follow-up for eighteen months revealed a complete remission. This is the first report on neoadjuvant PRRT in a neuroendocrine neoplasm with subsequent successful complete resection.
Kaemmerer
Daniel
D
Department of General and Visceral Surgery, Zentralklinik Bad Berka, 99437 Bad Berka, Germany. d.kaemmerer.avc@zentralklinik-bad-berka.de
Prasad
Vikas
V
Daffner
Wolfgang
W
Hörsch
Dieter
D
Klöppel
Günter
G
Hommann
Merten
M
Baum
Richard P
RP
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D020360:Neoadjuvant Therapy / Q000379:methods*; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011868:Radioisotopes / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000378:metabolism*; D016896:Treatment Outcome
D011868:Radioisotopes; D018000:Receptors, Peptide